[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zai Lab (Shanghai) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":184},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,71,94,115,137,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641587","phase-1-a-phase-1-study-to-evaluate-pharmacokinetics-safety-and-tolerability-of-zl-1503-in-healthy-volunteers-100641587",false,"NCT07658482","A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers","A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-1503 Following a Single Dose of Subcutaneous or Intravenous Administration in Healthy Volunteers.","Inclusion Criteria:\n\n* Healthy male and female volunteers, 18-65 years of age\n* Body mass index (BMI) between ≥ 18.5 and \\\u003C 32.5 kg\u002Fm2\n* Negative pregnancy tests for women of childbearing potential.\n\nExclusion Criteria:\n\n* Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.\n* History of major metabolic, liver, kidney, hematologic or other significant disorders.\n* Abnormal Electrocardiogram (ECG) findings\n* Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.\n* History of drug abuse or addiction within 6 months prior to screening\n* Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.\n* Donated \\>500mL blood within 2 months of dosing.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single subcutaneous (SC) or intravenous (IV) administration in healthy volunteers.",[28],"Healthy Volunteers",[30],"Healthy volunteers","NOT_YET_RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":22},"2026-09-03",{"date":39,"type":22},"2027-11-10",{"name":41,"class":42},"Zai Lab (Shanghai) Co., Ltd.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100621763","phase-1-phase-1ab-study-of-zl-6201-safety-pk-and-preliminary-efficacy-in-sarcoma-and-selected-tumors-100621763","NCT07374848","Phase 1a\u002Fb Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors","An Open-label, Phase 1a\u002Fb, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors","Inclusion Criteria:\n\n* Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \\> 3 months\n* Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and\u002For metastatic sarcoma or a selected solid tumor\n* Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample\n* Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting\n* Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic\u002Frelapsed refractory setting\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Adequate organ and marrow function as listed per protocol\n* Must be negative for HIV, HBV, and HCV\n\nExclusion Criteria:\n\n* Participants with another known malignancy that has required treatment within the last 2 years\n* Symptomatic central nervous system (CNS) metastasis, and\u002For those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms\n* Participants with leptomeningeal metastasis\n* Most recent systemic anti-cancer treatment or investigational products\u002Fdevices less than 3 weeks\n* Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions\n* Pregnant or nursing (lactating) women",{"count":52,"type":22},180,[25],"The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.",[56,57],"Solid Tumors","Sarcomas",[59,56,60,61,62],"Sarcoma","Phase1","Antibody-Drug Conjugate (ADC)","Leucine-Rich Repeat-Containing protein 15 (LRRC15)","RECRUITING",{"date":34,"type":35},{"date":66,"type":35},"2026-03-02",{"date":68,"type":22},"2029-09",{"name":41,"class":42},6,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100609712","phase-3-a-study-of-zl-1310-versus-investigators-choice-of-therapy-in-participants-with-relapsed-small-cell-lung-cancer-dllevate-100609712","NCT07218146","A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer","DLLEVATE","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years, or considered an adult by local regulations, at the time of consent\n* Signed informed consent\n* Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed.\n* Measurable disease according to RECIST v1.1 as assessed by the investigator.\n* Participants with a history of treated and stable or untreated and asymptomatic CNS metastases based on criteria per protocol.\n* Adequate organ and marrow function\n* Eastern Cooperative Group (ECOG) performance status of 0 or 1\n* Life expectancy of at least 3 months\n* Participants must be willing to undergo a tumor biopsy or provide archived tumor tissue sample at Screening\n* Participants must be willing and able to comply with protocol for the duration of the study\n\nExclusion Criteria:\n\n* Received more than one line of systemic therapy for Extensive-Stage SCLC.\n* Received any prior ADC with topoisomerase 1 inhibitor payload\n* Participants with another known malignancy with exceptions defined in the protocol.\n* History or suspected ILD\u002Fpneumonitis based on criteria per protocol\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.\n* Receipt of anti-cancer treatment known to treat cancers within 3 weeks before the first dose of study treatment.\n* Prior radiotherapy before study treatment based on criteria per protocol\n* Unresolved toxicity of Grade \\>\u002F= 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation.\n* Known infection or active infection defined in the protocol.\n* Clinically significant active cardiovascular disease or history of arterial thromboembolic event within 6 months prior to the first dose of study treatment based on criteria per protocol.",{"count":80,"type":22},480,[82],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.",[85],"Small-cell Lung Cancer",{"date":87,"type":35},"2026-06-23",{"date":89,"type":35},"2025-11-30",{"date":91,"type":22},"2028-11-30",{"name":41,"class":42},66,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":99,"conditions":105,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100584126","phase-1-a-study-of-zl-1310-in-participants-with-selected-solid-tumors-100584126","NCT06885281","A Study of ZL-1310 in Participants With Selected Solid Tumors","A Phase 1b\u002F2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors","Inclusion Criteria:\n\n* Signed informed consent\n* Adult men and women ≥18 years of age\n* Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC), and must have experienced disease progression on or after platinum-based therapy\n* Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Participants with another known malignancy that is progressing or requires active treatment within the last 2 years\n* Clinically active central nervous system (CNS) metastases\n* Participants with leptomeningeal metastasis\n* Participants who have received any ADC with a payload of topoisomerase I inhibitor (e.g., exatecan derivative)\n* Treatment with any systemic anti-cancer treatment or other investigational products\u002Fdevice within 3 weeks before the first dose of study treatment\n* Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to the thoracic area prior to first dose of study treatment or a history of radiation pneumonitis\n* Major surgery within 4 weeks of the first dose of study treatment\n* Hypersensitivity to any ingredient of the study treatment\n* Out of range value (as defined in protocol) within 10 days prior to the first dose of study treatment\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Lung-specific intercurrent clinically significant illnesses and any autoimmune, connective tissue, or inflammatory disorders including but not limited to pneumonitis\n* Has a history of (noninfectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at Screening\n* Pregnant or nursing (lactating) women\n* Participants who have been on concomitant strong CYP3A or CYP2D6 inhibitors within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer",{"count":102,"type":22},112,[25,104],"PHASE2",[56],"2026-05-07",{"date":108,"type":35},"2026-05-08",{"date":110,"type":35},"2025-05-12",{"date":112,"type":22},"2027-12",{"name":41,"class":42},21,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100529845","phase-1-a-study-of-zl-1310-in-subjects-with-small-cell-lung-cancer-100529845","NCT06179069","A Study of ZL-1310 in Subjects With Small Cell Lung Cancer","An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer","Inclusion Criteria:\n\n* Signed informed consent\n* Participant with metastatic or extensive-stage small cell lung cancer (de novo, not transformed) and for Part 1A and 1B must have documented disease progression during or following a platinum-based chemotherapy regimen. For Part 1C and Part 4, no prior systemic treatment for SCLC (including chemoradiotherapy for limited-stage SCLC). For Part 1B backfill and Part 3, first-line setting: no prior systemic treatment for SCLC (including chemoradiotherapy for limited-stage SCLC); or, first-line maintenance setting: participants have received at least 4 cycles of 1L induction therapy with carboplatin or cisplatin, etoposide, and anti-PD-L1 inhibitor for ES-SCLC with ongoing CR, PR, or SD per RECIST v1.1 assessed by the investigator. For Part 2-1, participants must have received no more than 2 lines of prior therapies in the extensive-stage setting, and progressed on or after a platinum-based chemotherapy regimen AND an anti-DLL3 T-cell engager (TCE). For Part 3, participants have received at least 4 cycles of 1L induction therapy with carboplatin or cisplatin etoposide, and anti-PD-L1 inhibitor for ES-SCLC with ongoing CR, PR, or SD per RECIST v1.1 assessed by the investigator.\n* Adult men and women ≥18 years of age.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Subjects must have at least one measurable target lesion as defined by RECIST v1.1 on CT, PET\u002FCT, or MRI.\n* Subjects must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample at screening per protocol guidelines.\n* Life Expectancy \\>\u002F= 3 months.\n\nExclusion Criteria:\n\n* Participants with another known malignancy that is progressing or requires active treatment within the last 2 years. Exceptions: basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin with previously administered curative treatment, in situ cervical cancer, or other cancers that do not require systemic anti-cancer therapies and will not impact life expectancy.\n* Symptomatic or untreated brain metastasis requiring concurrent treatment. For Part 2, Part 3, and Part 4 the following subjects can be enrolled if they have a stable neurologic status for at least 2 weeks prior to the first dose of ZL-1310:\n\n  1. Subjects with untreated and asymptomatic brain metastases.\n  2. Subjects with treated brain metastases that are no longer symptomatic (i.e. without neurologic signs or symptoms), who require no treatment with steriods or anticonvulsants and have recovered from the actue toxic effects of radiotherapy.\n* Subjects with leptomeningeal disease.\n* Treatment with any systemic anti-cancer treatment or other investigational products\u002F device within 3 weeks before first dose of study treatment.\n* Non-palliative radiotherapy within 2 weeks prior to first dose of study treatment or have had a history of radiation pneumonitis.\n* Major surgery within 4 weeks of the first dose of study treatment.\n* Hypersensitivity to any ingredient of the study treatment.\n* Inadequate organ function (as defined in protocol) within 10 days prior to the first dose of study treatment,\n* Participants with a diagnosis of immunodeficiency or receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer.\n* Participants have received a live or live-attenuated vaccine within 30 days of planned start of study therapy.\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Lung-specific intercurrent clinically significant illnesses and any autoimmune, connective tissue, or inflammatory disorders, including but not limited to pneumonitis.\n* Pregnant or nursing (lactating) women.\n* Participants who have been on concomitant strong CYP3A or CYP2D6 inhibitors within 14 days or 5 half-lives before the first study treatment, whichever is longer.\n* For Part 1C and Part 4 (ZL-1310 in combination with Atezolizumab and Carboplatin), participants who received prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies.\n* For Part 1B (ZL-1310 in combination with Atezolizumab) and Part 1C (ZL-1310 in combination with Atezolizumab and Carboplatin), participants who received systemic immunostimulatory agents (including but not limited to, IFNs and IL2) within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to the initiation of study treatment.",{"count":123,"type":22},339,[25],"An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer",[127],"SCLC","2026-03-30",{"date":130,"type":35},"2026-04-03",{"date":132,"type":35},"2024-01-23",{"date":134,"type":22},"2027-07-31",{"name":41,"class":42},38,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100609224","phase-3-a-study-to-assess-the-efficacy-and-safety-of-zl-1109-in-chinese-participants-with-active-thyroid-eye-disease-100609224","NCT07211776","A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease","A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)","Key Inclusion Criteria:\n\n1. Have moderate to severe TED\n2. Must meet the clinical diagnosis criteria of active TED\n3. Must agree to use highly effective contraception as specified in the protocol\n4. Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n1. Have received prior treatment with another anti-IGF-1R mAb or anti-thyroid stimulating hormone receptor (TSHR) mAb.\n2. Have received systemic corticosteroids or steroid eye drops for any condition, or other immunosuppressive drugs for any condition, including TED, or radioactive iodine (RAI) treatment within a certain period prior to first dose.\n3. Have corneal decompensation in the study eye unresponsive to medical management.\n4. Have a pre-existing ophthalmic in the study eye which in the opinion of the Investigator, would confound interpretation of the study results.","75 Years",{"count":146,"type":22},99,[82],"A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)",[150],"Thyroid Eye Disease (TED)",[150],"2025-12-24",{"date":154,"type":35},"2025-12-29",{"date":156,"type":35},"2025-12-05",{"date":158,"type":22},"2028-01-29",{"name":41,"class":42},27,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":43},"100611038","phase-1-a-phase-11b-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-zl-1503-in-healthy-volunteers-and-participants-with-moderate-to-severe-atopic-dermatitis-100611038","NCT07235384","A Phase 1\u002F1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis","A Phase 1\u002F1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Part A:\n\n  1. Healthy male and female volunteers, 18-65 years of age\n  2. Body mass index (BMI) between ≥ 18.5 and \\\u003C 32.5 kg\u002Fm2\n  3. Negative pregnancy tests for women of childbearing potential.\n* Part B:\n\n  1. 18-65 years of age;\n  2. BMI between ≥18.5 and \\\u003C40.0 kg\u002Fm2\n  3. Have a diagnosis of AD at least 12 months prior to Day 1;\n  4. Moderate-to-severe AD at Screening and Baseline visit, defined as:\n\n     1. Eczema Area and Severity Index (EASI) score ≥ 16;\n     2. Affected Body Surface Area (BSA)≥ 10%;\n     3. vIGA-AD™ score ≥ 3\n  5. History of an inadequate response to treatment with topical medications\n  6. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.\n  7. Negative pregnancy tests for women of childbearing potential.\n\nExclusion Criteria:\n\n* Part A and B:\n\n  1. Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.\n  2. History of major metabolic, liver, kidney, hematologic or other significant disorders.\n  3. Abnormal Electrocardiogram (ECG) findings\n  4. Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.\n  5. History of drug abuse or addiction within 6 months prior to screening\n  6. Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.\n  7. Donated \\>500mL blood within 2 months of dosing.\n* For Part B only:\n\n  1. Presence of dermatologic conditions and\u002For comorbidities that might confound the diagnosis of AD and\u002For might interfere with study assessments.\n  2. Uncontrolled chronic disease that might require bursts of oral corticosteroids.\n  3. Any other sound medical, psychiatric, and\u002For social reason as determined by the investigator.",{"count":169,"type":22},84,[25],"This is a phase 1\u002F1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)",[173],"Atopic Dermatitis (AD)",[175],"Atopic Dermatitis","2025-12-18",{"date":178,"type":35},"2025-12-19",{"date":180,"type":35},"2025-12-01",{"date":182,"type":22},"2027-12-28",{"name":41,"class":42},""]